Howard Berman, Coya Therapeutics CEO
November 21, 2022 11:37 AM EST
Financing
R&D

Six-per­son ALS biotech wants to go pub­lic — but it’s al­so piv­ot­ing from ear­li­er plans

Lei Lei Wu

News Reporter

With an S-1 fil­ing with the SEC on Fri­day, reg­u­la­to­ry T cell op­er­a­tion Coya Ther­a­peu­tics fore­shad­owed its plans to get on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times